Page last updated: 2024-09-05

lapatinib and zm 252868

lapatinib has been researched along with zm 252868 in 1 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(zm 252868)
Trials
(zm 252868)
Recent Studies (post-2010) (zm 252868)
1,9193051,4421401

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)zm 252868 (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.0714
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.143
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.049

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Almenara, JA; Campbell, DJ; Dewitt, JL; Oyesanya, RA; Sirica, AE; Zhang, Z1

Other Studies

1 other study(ies) available for lapatinib and zm 252868

ArticleYear
Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Tyrphostins

2010